Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa
Authors:
Open Access
- 1 January 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 160 (1) , 63-70
Abstract
Hidradenitis suppurativa is a chronic, immune-mediated, inflammatory skin disease that has a profound negative influence on the patients’ quality of life, affecting approximately 1% of the population.1 The disease often presents during adolescence with painful inflammatory nodules and abscesses that may form tunnels and result in extensive scarring, manifesting predominantly in axillary, inguinal, inframammary, and anogenital regions, but other regions may also be affected.2 Although the exact pathogenic mechanisms remain partly unknown, aberrant inflammation plays a crucial role in the pathogenesis.3 The cutaneous changes in hidradenitis suppurativa seem to start around hair follicles and involve activation of cells of both the innate and adaptive immune system. Furthermore, pivotal roles for a number of proinflammatory cytokines and signaling pathways, including tumor necrosis factor (TNF), interleukin (IL)-1β, IL-17, and IL-36, have been described.4Keywords
This publication has 28 references indexed in Scilit:
- HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab studyJournal of the European Academy of Dermatology and Venereology, 2015
- Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phaseAnnals of Oncology, 2015
- Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatmentBritish Journal of Dermatology, 2014
- Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosusCellular & Molecular Immunology, 2012
- Hidradenitis SuppurativaNew England Journal of Medicine, 2012
- Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo studyBritish Journal of Dermatology, 2011
- A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativaBritish Journal of Dermatology, 2011
- EC144, a Synthetic Inhibitor of Heat Shock Protein 90, Blocks Innate and Adaptive Immune Responses in Models of Inflammation and AutoimmunityThe Journal of Immunology, 2011
- Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritisArthritis & Rheumatism, 2008
- Heat Shock Protein 90 Inhibitors Prolong Survival, Attenuate Inflammation, and Reduce Lung Injury in Murine SepsisAmerican Journal of Respiratory and Critical Care Medicine, 2007